pharmaphorum

MARCH 23, 2021

AstraZeneca has been rebuked by a US health authority after a trial monitoring board said data published from a large study of its COVID-19 vaccine may be out of date and may not give a representative view of its efficacy. The post Doubts emerge over AZ’s ‘outdated’ US vaccine trial data appeared first on.

Vaccination 98

Vaccination Vaccine Trials Allergies 98

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . The Phase I trial (IAVI G001) tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing.

Vaccination 52

Vaccination Vaccine Trials Antibody 52

Scienmag

MARCH 15, 2021

The first vaccine has been administered in a comparative adjuvant trial of DNA prime/protein boost HIV vaccine regimens in Kericho, Kenya Credit: U.S. Military HIV Research Program SILVER SPRING, Md.

Vaccination 68

Vaccination Vaccine Trials DNA 68

XTalks

AUGUST 13, 2020

As the rush for a COVID-19 vaccine continues, healthcare services company Kaiser Permanente has joined in on the clinical testing of Pfizer Inc. and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

pharmaphorum

JULY 12, 2022

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. “The need for a preventive Nipah virus vaccine is significant,” he added. .

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. BacTRL Gene Therapy Platform.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

The Pharma Data

DECEMBER 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccination 52

Vaccination Vaccine Trials Development 52

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response.

Vaccination 69

Vaccination Vaccine Trials Immune Response 69

XTalks

SEPTEMBER 8, 2020

Albany Molecular Research Inc (AMRI), a global provider of advanced drug development and manufacturing solutions, announced that they have signed a supply agreement with AstraZeneca. The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

The Pharma Data

OCTOBER 22, 2020

Moderna has completed enrollment of 30,000 participants for its phase 3 study evaluating COVID-19 vaccine candidate mRNA-1273. The randomized, placebo-controlled trial is being conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and HHS’ Biomedical Advanced Research and Development Authority.

Vaccination 52

Vaccination Vaccine Trials Allergies 52

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

SEPTEMBER 1, 2020

AstraZeneca has started a Phase 3 trial of its experimental coronavirus vaccines in the US, making it the third company to start late-stage trials of a vaccine. . The trial will see participants receive either two doses of the vaccine or a placebo. Photo by Daniel Paquet from Regina, Canada.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Scienmag

JUNE 27, 2021

Study points towards role of gut microbiome in vaccine effectiveness Credit: Image by Dr. Hiroshi Kiyono, CC BY 4.0 A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice. The first human trial has shown no obvious side effects and a good immune response.

Vaccination 72

Vaccination Vaccine Immune Response Trials 72

Drug Discovery World

JULY 19, 2022

An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection. . The clinical trial has been launched by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate an investigational vaccine to prevent infection with Nipah virus. Fauci, M.D.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Vaccination 52

XTalks

NOVEMBER 16, 2020

Moderna announced today that its highly anticipated COVID-19 vaccine candidate appears to be 94.5 This is according to preliminary trial data from the company’s ongoing study that involves 30,000 people in the US. Moderna’s mRNA vaccine candidate — mRNA-1273 — was developed using its proprietary mRNA technology platform.

Vaccination 105

Vaccination Vaccine Trials Allergies 105

Scienmag

SEPTEMBER 8, 2020

September 9, 2020 – SEOUL, South Korea – The International Vaccine Institute (IVI) announced today that the Bill & Melinda Gates Foundation awarded close to 1.5 Following successful completion […].

Clinical Trials 45

Clinical Trials Clinical Trials Trials Vaccination 45

Scienmag

JANUARY 11, 2021

Scientists reach new milestone in vaccine development for neglected tropical disease Researchers have taken an important step forward in developing a controlled human infection model to test leishmaniasis vaccines.

Scientist 40

Scientist Vaccination Vaccine Development 40

The Pharma Data

MARCH 31, 2022

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

The Pharma Data

DECEMBER 17, 2020

Advisory Committee Votes to Recommend EUA for Moderna Vaccine. 17, 2020 — The Moderna COVID-19 vaccine received recommendation from a U.S. Food and Drug Administration advisory committee on Thursday, clearing the way for it to become the second COVID-19 vaccine to be granted emergency use authorization. THURSDAY, Dec.

Vaccination 52

Vaccination Vaccine Allergies Clinical Trials 52

The Pharma Data

JANUARY 29, 2021

29, 2021 — Interim phase 3 data show that the COVID-19 vaccine developed by Janssen Pharmaceuticals of Johnson & Johnson is 66 percent effective in preventing moderate-to-severe COVID-19 in adults, the National Institutes of Health announced today. The vaccine, known as Ad.26.COV2.S, The vaccine, known as Ad.26.COV2.S,

Vaccination 52

Vaccination Vaccine Allergies Clinical Trials 52

Scienmag

NOVEMBER 4, 2020

The finding provides a surrogate for testing the effectiveness of vaccine candidates Credit: Jennifer Jenks, Duke University School of Medicine DURHAM, N.C.

Vaccination 63

Vaccination Vaccine Research Development 63

Scienmag

DECEMBER 9, 2020

Phase 2 trials in 1,200 adults, young children, and infants suggest new poliovirus vaccine may have the potential to overcome outbreaks caused by a mutated polio strain linked to the oral vaccine that typically circulates in areas of low immunisation coverage, and poses one of biggest barriers to eradication.

Immune Response 75

Immune Response Vaccination Vaccine Scientist 75

The Pharma Data

MARCH 2, 2021

Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. The terms of the EUA allow use of the vaccine while more data are gathered.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 21, 2020

Fauci ‘Cautiously Optimistic’ for COVID-19 Vaccine by Year’s End. the leading infectious disease expert in the United States, said on Wednesday he is “cautiously optimistic” that a COVID-19 vaccine will be ready by year’s end. Multiple studies are testing three vaccine approaches, Fauci said.

Vaccination 52

Vaccination Vaccine Allergies Trials 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. It is now following up with data from a small group of older adults, and they look positive. Targeted drug combo attacks breast cancer brain metastases in mice.

Vaccination 53

Vaccination Vaccine Research Trials 53

Scienmag

SEPTEMBER 4, 2020

The new paper reports the findings of two open-label, non-randomised phase 1/2 trials looking at a frozen formulation and a freeze-dried formulation of a two-part vaccine.

Vaccination 45

Vaccination Vaccine Trials Antibody 45

The Pharma Data

MARCH 22, 2021

79% vaccine efficacy at preventing symptomatic COVID-19. The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. The trial had a 2:1 randomisation of vaccine to placebo.

Trials 52

Trials Vaccination Vaccine Radiology 52

XTalks

NOVEMBER 30, 2023

Global entities such as the WHO, the Global Fund and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have developed comprehensive strategies aligned with Sustainable Development Goal (SDG) target 3.3, These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

DECEMBER 14, 2020

ICU nurse Sandra Lindsay, with Long Island Jewish Medical Center in Queens, New York, received the Pfizer-BioNTech COVID-19 vaccine. Food and Drug Administration (FDA) ’ s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. Both vaccines have demonstrated about 94-95% efficacy in clinical trials.

Vaccination 52

Vaccination Vaccine Allergies Genome 52

XTalks

JANUARY 27, 2021

COVID-19 vaccine maker Moderna announced this week that results from a study show that the shot is effective against some of the new circulating variants of SARS-CoV-2. In a news release from Moderna, the company reported that the administration of its COVID-19 vaccine induced antibody titers against both variants.

Vaccination 52

Vaccination Vaccine In-Vitro Protein 52

Scienmag

APRIL 10, 2021

[link] New York, NY (April 10, 2021) – A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase (..)

Vaccination 67

Vaccination Vaccine Development Clinical Trials 67

The Pharma Data

DECEMBER 17, 2020

Food and Drug Administration (FDA) ’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended the agency grant Moderna ’s COVID-19 vaccine emergency use authorization (EUA). A week ago, the FDA granted Pfizer-BioNTech’s COVID-19 vaccine EUA on Friday the day after the same adcom voted 16-1-1.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JUNE 16, 2023

France-based biotech company Osivax has thrown its hat into the influenza ring by dosing the first subject with its vaccine candidate OVX836. The Phase IIa trial (NCT05734040) in Australia will see a potential 500 volunteers given OVX836 in combination with quadrivalent influenza vaccines (QIVs).

Vaccination 246

Vaccination Vaccine Trials Immune Response 246

Drug Discovery World

JANUARY 21, 2024

Advances in this area are having a positive effect on both the commercial success of drug discovery and development organisations, as well as benefitting the health and wellbeing of the global population. His recent research focuses on vaccines against influenza and other (re)emerging viruses.

Protein 52

Protein Vaccination Vaccine Development 52

The Pharma Data

NOVEMBER 16, 2020

Moderna announced this week that its coronavirus vaccine, mRNA-1273, appears to not only be more effective than Pfizer’s candidate but has significantly less stringent temperature requirements as well, likely making distribution and storage of the vaccine an easier, less daunting task. percent efficacy rate.

Vaccination 40

Vaccination Vaccine Manufacturing Allergies 40

Drug Discovery World

NOVEMBER 2, 2022

“We need to expand the arsenal of available interventions to prevent malaria infection and accelerate efforts to eliminate the disease,” said Anthony S Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. . Trials in more potent antibody.

Antibody 52

Antibody Allergies Trials Medicine 52

The Pharma Data

DECEMBER 8, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Swiss Federal Government has increased its confirmed order commitment from 4.5 million doses of Moderna’s vaccine candidate against COVID-19 , mRNA-1273. “As

Vaccination 40

Vaccination Vaccine Manufacturing Containment 40